EU e-Privacy Directive

This website uses cookies to manage authentication, navigation, and other functions. By using our website, you agree that we can place these types of cookies on your device.

You have declined cookies. This decision can be reversed.


ICAN (Informed Consent Action Network) has written to the VRBPAC (Vaccine and Related Biological Products Advisory Committee) (approximately the equivalent of our own JCVI Joint Committee on Vaccines and Immunisation) to urge them not to approve Pfizer's application for emergency authorisation for their Covid vaccine for children below the age of 5.

They make the pertinent (and seemingly unarguable) point that there is no Covid emergency for this age group. Mind you, this point would seem equally applicable for ages 5 to 18 and beyond.

"As of January 19, 2022, the rate of hospitalization in children under 4 years old was reported to be just 6 per 100,000" - although the true rate is likely even lower if those that died "with Covid" rather than "of Covid" are stripped out.

The letter to VRBPAC also goes into the serious efficacy and safety issues with this vaccine and you can download the entire letter, which has other pertinent points to make:

"The Clinical Trial and Resulting Data is Wholly Inadequate to Support Authorization for This Age Group

"Pfizer announced it was 'initiat[ing] a rolling submission' of its data on February 1, 2022 'following a request from the [FDA].' 17 Your committee will meet to discuss this incomplete data only two weeks later. This is incredible and cannot possibly be adequate time in which to confirm, analyze, and assess such critical data."

There is more, including an identified mismatch between the application for authorisation (a two dose schedule) and the latest proposed dosage (a three dose schedule for which data is as yet unavailable) ...

Worth reading, if only to get a flavour of the proceedings of those entrusted with protecting the public from the products of unscrupulous pharmaceutical companies.